AGM
AIMT

Alpine Global Management’s Aimmune Therapeutics AIMT Stock Holding History

Alpine Global Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29,937
Closed -$805K – 106
2018
Q2 		$805K Sell
29,937
-2,563
-8% -$78.4K 0.39% 35
2018
Q1 		$1.03M Buy
+32,500
New +$1.14M 0.24% 50

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alpine Global Management's AIMT Position: Q3 2018 in Review

Alpine Global Management sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 29,937 shares — an estimated $805K sold.

Alpine Global Management first reported a position in AIMT in Q1 2018 and held it in 2 quarters. The position peaked at $1.03M in Q1 2018. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Alpine Global Management reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Alpine Global Management sold 29,937 Aimmune Therapeutics shares in Q3 2018, an estimated $805K.
  • Alpine Global Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 2 quarters.
  • Alpine Global Management's Aimmune Therapeutics position peaked at $1.03M in Q1 2018.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Alpine Global Management's 13F filing for Q3 2018, filed 15 Nov 2018.